Short-Term PTEN Inhibition Improves In Vitro Activation of Primordial Follicles, Preserves Follicular Viability, and Restores AMH Levels in Cryopreserved Ovarian Tissue From Cancer Patients

PLoS One. 2015 May 29;10(5):e0127786. doi: 10.1371/journal.pone.0127786. eCollection 2015.

Abstract

Introduction: In vitro activation and growth of primordial dormant follicles to produce fertilizable oocytes would provide a useful instrument for fertility preservation. The employment of Phosphatase and TENsin homolog (PTEN) inhibitors, in combination with Protein kinase B (Akt) stimulating molecules, has been previously employed to increase follicular activation through the stimulation of the PTEN-Akt pathway.

Methods: We aim to establish improved in vitro activation also for cancer patients whose ovarian tissue has already been cryopreserved. Fresh and previously cryopreserved human ovarian cortex were exposed to short-term, low-concentration and ovary-specific treatment with only a PTEN inhibitor.

Results: Our in vitro activation protocol enhances the activation mechanisms of primordial follicles in both fresh and cryopreserved samples, and enlarges growing populations without inducing apoptosis in either follicles or the surrounding stroma. Treatment augments estradiol secretion and restores the expression levels of the previously diminished Anti-Müllerian hormone by means of cryopreservation procedures. Genomic modulation of the relative expression of PTEN pathway genes was found in treated samples.

Conclusion: The in vitro activation protocol offers new alternatives for patients with cryopreserved tissue as it increases the pool of viable activated follicles available for in vitro growth procedures. The combination of ovarian tissue cryopreservation and in vitro activation of primordial follicles, the main ovarian reserve component, will be a major advancement in fertility preservation.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Mullerian Hormone / biosynthesis*
  • Cryopreservation*
  • Enzyme Inhibitors / pharmacology*
  • Female
  • Humans
  • Neoplasms*
  • Organ Preservation*
  • Ovarian Follicle / metabolism*
  • PTEN Phosphohydrolase / antagonists & inhibitors*
  • PTEN Phosphohydrolase / biosynthesis
  • Tissue Survival

Substances

  • Enzyme Inhibitors
  • Anti-Mullerian Hormone
  • PTEN Phosphohydrolase
  • PTEN protein, human

Grants and funding

This work has been supported by Grants SAF 2011-30031-CO2-01 and FIS PI13/02353 from the Spanish Ministry of Economy and Competitiveness, by the Dexeus Women's Health Foundation Grant 2011 and by PROMETEOII/2014/045 and GV/2014/115 by the Regional Valencian Ministry of Education. SH participation has been supported by a grant CD11/00292 from the Spanish Ministry of Economy and Competitiveness and BRI by AP-2010-0675 grant from the Spanish Ministry of Education, Culture and Sport. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.